| 摘要: |
| 摘要 目的：探讨补体应答基因32（RGC32）在食管癌组织中的表达，及其与临床病理特征和预后的关系。方法：回顾性分析2017年1月至2020年6月第九〇九医院收治行胸段食管癌根治术79例患者临床病理资料。采用免疫组织化学法检测食管癌组织和癌旁组织中RGC32蛋白表达水平，分析癌组织中RGC32蛋白表达与临床病理特征关系，单因素和Logistic多因素分析食管癌患者预后不良的影响因素，绘制Kaplan Meier曲线分析癌组织中RGC32蛋白表达与生存关系。结果：食管癌组织RGC32蛋白阳性率63.29%高于癌旁组织16.46%（c2=15.172，P<0.001）。肿瘤长径≥3 cm、淋巴结转移、TNM分期Ⅲ期、随访期间内死亡的患者RGC32蛋白表达阳性率高于肿瘤长径<3 cm、淋巴结无转移、TNM分期Ⅰ～Ⅱ期、存活的患者，差异有统计学意义（P<0.05）。单因素分析发现肿瘤长径≥3 cm、淋巴结转移、TNM分期Ⅲ期与患者的不良预后相关（P<0.05）。多因素分析发现肿瘤长径≥3 cm（OR：5.429，95%CI：1.241～13.756）、淋巴结转移（OR：6.353，95%CI：1.439～18.047）、TNM分期Ⅲ期（OR：8.926，95%CI：2.060～18.686）、癌组织RGC32蛋白表达阳性（OR：9.116，95%CI：1.758～16.584）是食管癌患者预后不良的独立危险因素。Kaplan Meier曲线分析发现癌组织RGC32蛋白表达阳性患者3年存活率35%低于RGC32蛋白表达阴性患者的82.1%（Log-rank=19.154、P<0.001）。结论：食管癌患者中RGC32蛋白阳性表达与肿瘤大小、淋巴结转移、TNM分期等不良病理学特征相关，是者预后不良的独立危险因素，可以作为预后评估指标。 |
| 关键词: 食管癌 补体应答基因32 预后 食管切除术 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Expression and clinical significance of RGC32 in esophageal carcinoma |
|
黄江宾, yule, kuiguoju, yanglimin, mengjiarong
|
|
The 909th Hospital(Dongnan Hospital of Xiamen University)
|
| Abstract: |
| Abstract Objective：To investigate the expression of complement response gene 32 (RGC32) in esophageal carcinoma and its relationship with clinicopathological features and prognosis.Methods:The clinicopathological data of 79 patients who underwent radical resection for thoracic esophageal cancer treated in the 909th Hospital from January 2017 to June 2020 were retrospectively analyzed.The expression of RGC32 protein in esophageal carcinoma tissues and adjacent tissues was detected by immunohistochemistry.The relationship between the expression of RGC32 protein and clinicopathological features in cancer tissues was analyzed. Univariate and Logistic multivariate analysis were performed to analyze the influencing factors of poor prognosis in patients with esophageal cancer, and Kapln was plotted. The relationship between RGC32 protein expression and survival in cancer tissues was analyzed by Meier curve.
Results:The positive rate of RGC32 protein in esophageal cancer tissues was 63.29% higher than 16.46% in adjacent tissues (c2=15.172, P<0.001).The positive rate of RGC32 protein expression in patients with tumor length ≥3 cm, lymph node metastasis, TNM stage Ⅲ, and death during follow-up were higher than that in patients with tumor length <3 cm, no lymph node metastasis, TNM stage Ⅰ to Ⅱ, and survival, the difference was statistically significant (P<0.05).Univariate analysis showed that tumor length ≥3 cm, lymph node metastasis and TNM stage Ⅲ were associated with poor prognosis (P<0.05).Multivariate analysis showed tumor size ≥3 cm (OR: 5.429, 95%CI: 1.241～13.756), lymph node metastasis (OR: 6.353, 95%CI: 1.439～18.047), TNM stage III (OR: 8.926, 95%CI: 2.060～18.686) and positive expression of RGC32 protein in cancer tissues (OR: 9.116, 95%CI: 1.758～16.584) were independent risk factors for poor prognosis in patients with esophageal cancer.Kaplan-Meier curve analysis showed that the 3-year survival rate of patients with positive expression of RGC32 protein was 35% lower than that of patients with negative expression of RGC32 protein（Log-rank=19.154、P<0.001）.Conclusions:The positive expression of RGC32 protein in patients with esophageal cancer is correlated with tumor size, lymph node metastasis, TNM stage and other adverse pathological features. It is an independent risk factor for poor prognosis and can be used as a prognostic indicator. |
| Key words: Esophageal cancer Complement response gene 32 Prognosis Esophagectomy |